Renal Business Today

Soluble Ferric Pyrophosphate (SFP)

Rockwell Names VP of Drug Development, Medical Affairs

WIXOM, Mich.—Rockwell Medical has hired Annamaria T. Kausz, MD, MS, to replace Dr. Richard Yocum as Vice President of Drug Development and Medical Affairs. ...More
September 19, 2011
Posted in News, Business
Rockwell Receives Patent for SFP Packaging, Method of Use

WIXOM, Mich.—The U.S. Patent and Trademark Office has issued a patent to Rockwell Medical for the packaging and method of use for its proprietary iron drug Soluble Ferric Pyrophosphate (SFP). ...More
May 11, 2011
Posted in News, Business, Government & Regulation
Rockwell Begins Second Phase III Clinical Trial for Iron Drug

WIXOM, Mich.—Rockwell Medical announced April 26 that it has initiated enrollment in its second pivotal Phase III clinical study called CRUISE-2, designed to treat iron deficiency anemia in hemodialysis dependent-chronic kidney disease patients receiving erythropoietin. ...More
April 26, 2011
Posted in News, Business, Clinical & Pharma
Rockwell Starts Phase 3 Enrollment of Iron Study

WIXOM, Mich.—Rockwell Medical has started enrollment in its phase 3 CRUISE-1 clinical study, designed to treat iron deficiency anemia in hemodialysis dependent-chronic kidney disease patients receiving erythropoietin. ...More
March 24, 2011
Posted in News, Clinical & Pharma
LDOs to Participate in Rockwell Iron Drug Studies

WIXOM, Mich.—The clinical research divisions if the two largest dialysis companies have signed agreements to participate in Rockwell Medical’s phase III studies using Soluble Ferric Pyrophosphate (SFP) as a continuous iron replacement therapeutic. ...More
January 26, 2011
Posted in News, Business, Clinical & Pharma
Rockwell to Start SFP Phase III Trials Within 90 Days

WIXOM, Mich.—Rockwell Medical has released the design of its Phase III development program for Soluble Ferric Pyrophosphate (SFP) and will begin the clinical studies within 90 days, according to a news release. ...More
October 20, 2010
Posted in News, Business, Clinical & Pharma, Government & Regulation
Rockwell Appoints Macdougall to Scientific Advisory Board

WIXOM, Mich.—Rockwell Medical has appointed Iain Macdougall, BSc(Hons), MD, FRCP, to its scientific advisory board (SAB). ...More
August 19, 2010
Posted in News, Business
Rockwell Positions Iron Drug in Age of the Bundle

WIXOM, Mich.—Rockwell Medical finds itself in an interesting position—it has a profitable core business while it is developing a new product for the competitive iron drug market, both of which are in the rapidly changing economic environment of dialysis reimbursement. ...More
August 12, 2010 By Keith Chartier
Posted in Articles, Business
Rockwell, FDA Complete Phase II Meeting for Iron Drug

WIXOM, Mich.—Rockwell Medical said July 8 that it has successfully completed an “End of Phase II” meeting with the U.S. Food and Drug Administration (FDA) regarding its iron-replacement therapy for dialysis patients. ...More
July 8, 2010
Posted in News, Clinical & Pharma, Government & Regulation
Future Iron Treatments Shaped by New Payment Structures, Products

The choice of what iron product to use will be especially relevant with the bundled payment set to start in 2011. According to an August 2009 BioTrends report, dialysis clinic medical directors foresee the increased use of IV iron to spare the use of ESAs (such as Amgen’s ...More
January 29, 2010
Posted in Articles, Business, Clinical & Pharma, Practice Management

featured links

HOT TOPICS

Computers & Software	Consulting, Management...
Equipment & Services	Hemodialysis Supplies
Patient Services	More Options...

Soluble Ferric Pyrophosphate (SFP)

Mobile Health Snaps

Galleries

Most Popular Articles

Buyer's Guide

Resources

Free Email Updates

featured links

First Name	Last Name
E-Mail